{"schema_version":"secwatch.filing_event.v1","accession":"0001534120-25-000013","form_type":"8-K","ticker":"AVTX","cik":"0001534120","company_name":"Avalo Therapeutics, Inc.","filed_at":"2025-10-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.669895+00:00","generated_at":"2026-05-17T01:38:34.508355+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Avalo completes Phase 2 LOTUS enrollment for AVTX-009; topline data mid-2026","bullets":["Enrolled ~250 patients, exceeding the 222-patient target.","Trial is randomized, double-blind, placebo-controlled with two AVTX-009 dose regimens.","Primary endpoint is HiSCR75 at Week 16; topline results expected mid-2026.","CEO Dr. Garry Neil cited strong investigator and patient engagement due to high unmet need.","Trial identifier NCT06603077; details at clinicaltrials.gov or lotustrial.com."],"urls":{"canonical":"https://secwatch.observer/filing/0001534120-25-000013","json":"https://secwatch.observer/filing/0001534120-25-000013.json","markdown":"https://secwatch.observer/filing/0001534120-25-000013.md","text":"https://secwatch.observer/filing/0001534120-25-000013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000153412025000013/0001534120-25-000013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000153412025000013/avtx-20251029.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:38:34.508355+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}